Industrial Psychiatry Journal

ORIGINAL ARTICLE
Year
: 2013  |  Volume : 22  |  Issue : 2  |  Page : 149--152

An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder


Ajay Kumar Bakhla1, Vijay Verma1, Subhas Soren3, Sujit Sarkhel2, Suprakash Chaudhury3 
1 Department of Psychiatry, Ranchi Institute of Neuropsychiatry and Allied Sciences, Kanke, Ranchi, Jharkhand, India
2 Institute of Psychiatry, Kolkata, West Bengal, India
3 Department of Psychiatry, Pravara Institute of Medical Sciences (Deemed University), Rural Medical College, Loni, Maharashtra, India

Correspondence Address:
Suprakash Chaudhury
Department of Psychiatry, Pravara Institute of Medical Sciences (Deemed University), Rural Medical College, Loni - 413 736, Maharashtra
India

Background: Obsessive-compulsive disorder (OCD) is often refractory to treatment. Glutamatergic neurotransmission modulating agents like memantine, an N-methyl-D-aspartate receptor open channel blocker (antagonist), has been reported to be beneficial in OCD. Materials and Methods: Twelve subjects of OCD who had been on various medications for over 5 years, but were poor responders, were enrolled for a 12-week open-label trial with fixed dose trial of memantine as an augmenting agent. The OCD symptoms and adverse effects of the drug were monitored. Results: Out of 12 subjects, eight had clear benefit, with reduction of 25% or more on Yale-Brown Obsessive-Compulsive Scale, and there were no side-effects with the medication, Conclusion: Memantine may be beneficial for treatment-resistant OCD as an augmenting agent.


How to cite this article:
Bakhla AK, Verma V, Soren S, Sarkhel S, Chaudhury S. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder.Ind Psychiatry J 2013;22:149-152


How to cite this URL:
Bakhla AK, Verma V, Soren S, Sarkhel S, Chaudhury S. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder. Ind Psychiatry J [serial online] 2013 [cited 2019 Dec 14 ];22:149-152
Available from: http://www.industrialpsychiatry.org/article.asp?issn=0972-6748;year=2013;volume=22;issue=2;spage=149;epage=152;aulast=Bakhla;type=0